187 related articles for article (PubMed ID: 30316766)
1. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Bashash D; Delshad M; Riyahi N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2018 Dec; 841():10-18. PubMed ID: 30316766
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
[TBL] [Abstract][Full Text] [Related]
3. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
[TBL] [Abstract][Full Text] [Related]
4. Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
Bashash D; Delshad M; Safaroghli-Azar A; Safa M; Momeny M; Ghaffari SH
Int J Biochem Cell Biol; 2017 Oct; 91(Pt A):1-8. PubMed ID: 28834761
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
[TBL] [Abstract][Full Text] [Related]
6. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
8. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis.
Sayyadi M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Abolghasemi H; Anoushirvani AA; Bashash D
Arch Med Res; 2020 Oct; 51(7):636-644. PubMed ID: 32553459
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
[TBL] [Abstract][Full Text] [Related]
11. BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
Bashash D; Ghaffari SH; Zaker F; Kazerani M; Hezave K; Hassani S; Rostami M; Alimoghaddam K; Ghavamzadeh A
Anticancer Agents Med Chem; 2013 Sep; 13(7):1115-25. PubMed ID: 23293885
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
13. Suppression of proteasome induces apoptosis in APL cells and increases chemo-sensitivity to arsenic trioxide: Proposing a perception in APL treatment.
Zamani-Moghaddam N; Mousavi FS; Esmaeili S; Yousefi AM; Safaroghli-Azar A; Bashash D
Cancer Treat Res Commun; 2021; 26():100284. PubMed ID: 33387871
[TBL] [Abstract][Full Text] [Related]
14. Peroxiredoxin 3 Has Important Roles on Arsenic Trioxide Induced Apoptosis in Human Acute Promyelocytic Leukemia Cell Line via Hyperoxidation of Mitochondrial Specific Reactive Oxygen Species.
Mun YC; Ahn JY; Yoo ES; Lee KE; Nam EM; Huh J; Woo HA; Rhee SG; Seong CM
Mol Cells; 2020 Sep; 43(9):813-820. PubMed ID: 32975211
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of nvp-bkm120 in human osteosarcomas cells.
Bavelloni A; Focaccia E; Piazzi M; Orsini A; Ramazzotti G; Cocco L; Blalock W; Faenza I
J Cell Physiol; 2019 Jul; 234(7):10907-10917. PubMed ID: 30536897
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
Xu W; Li X; Quan L; Yao J; Mu G; Guo J; Wang Y
Leuk Lymphoma; 2018 Mar; 59(3):650-659. PubMed ID: 28679299
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Kumar S; Tchounwou PB
Environ Toxicol; 2021 Sep; 36(9):1785-1792. PubMed ID: 34042274
[TBL] [Abstract][Full Text] [Related]
19. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
Mosleh M; Safaroghli-Azar A; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105734. PubMed ID: 32119989
[TBL] [Abstract][Full Text] [Related]
20. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]